

## Competitive Deprotonation of 2-Hydrogen vs. 8-Hydrogen in Zwitterionic Purines

By JOHN L. WONG\* and JOHN H. KECK, JR.


(Department of Chemistry, University of Louisville, Louisville, Kentucky 40208)

**Summary** The generality and rates of the competitive deprotonations of the 2- vs. the 8-hydrogen in zwitterionic purines are shown and a mechanism is proposed.

ISOTOPIC hydrogen exchange at the 8-position of purines *via* a carbanion intermediate<sup>1</sup> is a reaction of biological significance which indicates that C-8 is a nucleophilic centre in purine nucleosides. Thus, the report by Bergmann *et al.*<sup>2</sup> that only the 2-hydrogen of 3-methylhypoxanthine exchanged in D<sub>2</sub>O at 70–85° is unique and interesting. We report now the generality of this purine 2-hydrogen deprotonation and propose a mechanism to account for the competitive exchanges of the 2- and 8-hydrogen atoms in these compounds.

Deprotonations were studied in D<sub>2</sub>O at pD 6–7 in a sealed tube heated at 100°C, and the exchanges were followed by <sup>1</sup>H n.m.r. technique. The Table shows the pseudo-first-order rate constants for the 2- and 8-proton exchange in three groups of purine compounds, the hypoxanthines, 6-mercaptapurines, and adenines. The hypoxanthines were stable throughout this treatment. 6-Mercaptopurine and the 1-methyl derivative decomposed at a rate slower than that of 8-H exchange but faster than that of 2-deprotonation; hence the latter was not determined directly. Since hydrolysis of 1-methyladenine preceded any carbon deuteration, it is not included in the Table.

Notable conclusions are (i) deuteration at the 2-position of a purine is significant ( $k_{\text{obs}}$  ca.  $10^{-5} \text{ s}^{-1}$ ) only with potential zwitterionic structures, *e.g.* (I) and (II), (ii) the 1-methyl group exerts a mildly rate-enhancing effect on both the 2- and 8-deprotonation, and (iii) the 3-methyl group leads to a rapid increase of the rate of deprotonation of the 2-hydrogen with concomitant depression of that of the 8-hydrogen, thus resulting in a dramatic increase of the



SCHEME. Deprotonation mechanism of zwitterionic purines *via* a conjugate acid carbanion.

TABLE. Rates of deuteration at 100°

	$\delta^a$		$k/s^{-1}$		$k(2-H)/k(8-H)$
	2-H	8-H	2-Position	8-Position	
Hypoxanthine <sup>b,f</sup> .. .. .	8.42	8.51	$9.75 \times 10^{-6}$	$2.80 \times 10^{-4}$	0.035
1-Methylhypoxanthine <sup>b</sup> .. .. .	8.60	8.50	$1.16 \times 10^{-5}$	$3.72 \times 10^{-4}$	0.031
3-Methylhypoxanthine <sup>b</sup> .. .. .	8.67	8.57	$2.22 \times 10^{-3}$	$2.04 \times 10^{-5}$	109.0
6-Methoxypurine 3-oxide <sup>b</sup> .. .. .	8.86	8.64	$6.85 \times 10^{-6}$	$1.08 \times 10^{-5}$	0.635
6-Mercaptopurine <sup>c</sup> .. .. .	8.28	8.43	$< 1.13 \times 10^{-6,e}$	$1.30 \times 10^{-6}$	$< 0.09$
1-Methyl-6-mercaptopurine <sup>c</sup> .. .. .	8.63	8.43	$< 1.30 \times 10^{-7,e}$	$1.38 \times 10^{-5}$	$< 0.01$
3-Methyl-6-mercaptopurine <sup>c</sup> .. .. .	9.32	8.60	$2.20 \times 10^{-4}$	$6.48 \times 10^{-7}$	340.0
Adenine <sup>d</sup> .. .. .	8.20	8.17	$1.72 \times 10^{-7}$	$1.10 \times 10^{-4}$	0.001
3-Methyladenine <sup>b</sup> .. .. .	8.30	8.07	$2.51 \times 10^{-5}$	$5.58 \times 10^{-7}$	45.0

<sup>a</sup> From internal sodium 3-(trimethylsilyl)propanesulphonate. Assignments are made according to J. R. Fox, Ph.D. Thesis, University of Illinois, Urbana, Illinois, 1965. <sup>b</sup> 0.1M Solution of the purine compound in D<sub>2</sub>O. pD of all solutions are in the range 6–7. <sup>c</sup> In (CD<sub>3</sub>)<sub>2</sub>SO–D<sub>2</sub>O (2:1). <sup>d</sup> J. A. Elvidge, J. R. Jones, and C. O'Brien, *Chem. Comm.*, 1971, 394, extrapolated from  $k$  (deuteration; 85°) using  $E = 22.3 \text{ kcal mol}^{-1}$ . <sup>e</sup> Rate of decomposition, hence the rate of exchange is less than this rate. <sup>f</sup> In (CD<sub>3</sub>)<sub>2</sub>SO–D<sub>2</sub>O (2:1) solution at 100°,  $k/s^{-1}$  for the 2- and 8-position are respectively  $6.95 \times 10^{-7}$  and  $1.84 \times 10^{-5}$ ,  $k(2-H)/k(8-H) = 0.038$ .

relative rate of 2-*vs.* 8-deprotonation by many orders of magnitude.

We<sup>3a</sup> and others<sup>3b</sup> have shown that deuteration of the 2-, 4-, and 5-position of imidazoles in D<sub>2</sub>O (pD 0–12) proceeds *via* a carbanionic mechanism occurring on the conjugate acid species. The same mechanism has been proposed for the 8-exchange of several 6-substituted purines by Maeda *et al.*<sup>1a</sup> and Olson *et al.*<sup>1b</sup> The Scheme illustrates this deprotonation mechanism for the 2- and 8-hydrogen of the zwitterionic purines. Similar zwitterionic structures have been postulated by Beak *et al.*<sup>4</sup> to explain the hydrogen deuterium exchange at the 2-position of an *N*-methyl-4-pyrimidone and a 1,3-dimethyl-4-pyrimidonium salt. Thus, N-3 or N-7 deuteration leads to the respective conjugate acid species for 2- and 8-deprotonation of (I). Since the basicity of N-7 and N-3 of (I) is enhanced when R is Me rather than H, the greater facility of forming the necessary conjugate acid species should yield a higher  $k_{obs}$  of exchange of 1-methylhypoxanthine than that of hypoxanthine. In

comparing the 3-methylhypoxanthine zwitterionic form (IIa) with (I), the basicity of N-7 in (IIa), on account of the direct attachment of the quaternized N-3 to the imidazole ring, must be significantly depressed relative to N-7 in (I). Conversely, N-1 in (IIa), being adjacent to the 6-oxy anion, should be much more basic than N-3 of (I). The combined effects of the N-3-quaternized structure (IIa) are that the  $k_{obs}$  of 2-deprotonation is enhanced while that of 8-deprotonation is depressed. Similar mechanisms appear to prevail for the deprotonation of the 3-methyl derivatives of 6-mercaptopurine (IIb) and adenine (IIc). For 6-methoxypurine *N*-oxide, the *N*-oxide deactivation of N-7 is expected to be less than for a genuine quaternary N-3. However, the activation of N-1 due to the more remote and less basic N-3-oxide anion is also less pronounced, hence a more subdued relative rate was obtained.

(Received, 6th May 1974; Com. 520.)

<sup>1</sup> (a) M. Maeda and M. Saneyoshi, *Chem. Pharm. Bull., Japan*, 1971, **19**, 1641; (b) M. Olson and J. Mercado, *Biochem.*, 1972, **11**, 1235.

<sup>2</sup> F. Bergmann and Z. Neiman, *Chem. Comm.*, 1969, 992.

<sup>3</sup> (a) J. L. Wong and J. H. Keck, Jr., *J. Org. Chem.*, 1974, **39**, 2398; (b) J. D. Vaughan, Z. Mughrabi, and E. C. Wu, *J. Org. Chem.*, 1970, **35**, 1141.

<sup>4</sup> P. Beak and E. M. Monroe, *J. Org. Chem.*, 1969, **34**, 589.